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ARTICLE
A Common Haplotype in the G-Protein–Coupled Receptor Gene
GPR74 Is Associated with Leanness and Increased Lipolysis
Ingrid Dahlman, Andrea Dicker, Hong Jiao, Juha Kere, Lennart Blomqvist, Vanessa van Harmelen,
Johan Hoffstedt, Knut Borch-Johnsen, Torben Jo¨rgensen, Torben Hansen, Oluf Pedersen,
Markku Laakso, and Peter Arner
The G-protein–coupled receptor GPR74 is a novel candidate gene for body weight regulation. In humans, it is predom-
inantly expressed in brain, heart, and adipose tissue.We report a haplotype in theGPR74 gene, ATAG,with allele frequency
∼4% in Scandinavian cohorts, which was associated with protection against obesity in two samples selected for obese
and lean phenotypes (odds ratio for obesity 0.48 and 0.62; nominal and .014; and 1,423, respectively).Pp .0014 np 1,013
In a population-based sample, it was associated with lower waist ( ) among 3,937 men and with obesity protectionPp .02
(odds ratio 0.36; ) among those selected for obese or lean phenotypes. The ATAG haplotype was associated withPp .036
increased adipocyte lipid mobilization (lipolysis) in vivo and in vitro. In human fat cells, GPR74 receptor stimulation
and inhibition caused a signiﬁcant and marked decrease and increase, respectively, of lipolysis, which could be linked
to catecholamine stimulation of adipocytes through b-adrenergic receptors. These ﬁndings suggest that a common hap-
lotype in the GPR74 gene protects against obesity, which, at least in part, is caused by a relief of inhibition of lipid
mobilization from adipose tissue. The latter involves a cross-talk between GPR74 and b-adrenoceptor signaling to lipolysis
in fat cells.
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Although it is generally accepted that heredity has a strong
inﬂuence on body weight, the resolution of the genetic
components underlying variability in BMI (calculated as
body weight in kilograms divided by the square of height
in meters) among the general population is incomplete.
In particular, the genetic factors that protect against obe-
sity are not well understood.1 The G-protein–coupled re-
ceptor 74 (GPR74 [MIM 607449]) is a novel candidate gene
for regulation of BMI. In humans, the receptor is predom-
inantly expressed in the brain, heart, and adipose tissue.2,3
The true endogenous ligand for the receptor is not known,
but GPR74 has a high afﬁnity for neuropeptides, such as
neuropeptide FF (NPFF).4 This neuropeptide has been in-
vestigated in laboratory animals. Although the opioid
modulating effects of NPFF are the best explored,5 NPFF
is also involved in cardiovascular regulation6 and response
to stress7 or reward.8 As summarized elsewhere,9 NPFF has
been reported to have effects on food intake. In addition,
NPFF has effects on rodent fat cells, which involve inter-
actions with b-adrenergic receptors.10 Catecholamines are
the most important lipolytic hormones in man, and they
regulate lipolysis through two major stimulatory adren-
oceptors, b1and b2 (b3 is less effective), and through one
inhibitory receptor (a2).
11 Taken together, these data sug-
gest that GPR74 could be a gene of importance for body
weight regulation, maybe by having effects mediated on
adipocyte lipolysis. We therefore did a comprehensive
analysis of genetic variance in the GPR74 gene, using a
large cohort of Swedish subjects with well-deﬁned criteria
for either long-standing leanness or severe obesity. The
most important polymorphismswere reinvestigated in an-
other large cohort of lean and obese Swedes, and results
were conﬁrmed in a large population-based Danish co-
hort. Finally, studies on lipolysis were performed, ﬁrst, to
ﬁnd a link between GPR74 polymorphisms and lipid mo-
bilization and, second, to study the mechanisms of action
for GPR74 on human fat-cell lipolysis.
Methods
Study Population
Sample 1 was recruited for a study of genes underlying suscep-
tibility to obesity, either from an outpatient center for treatment
of obesity or through local advertisement (ﬁg. 1 and table 1). The
subjects were carefully selected for a lean or obese phenotype,
and were at least 2nd-generation Scandinavians living in Sweden.
The obese subjects were either !21 years old with BMI 130 or any
age with BMI 140 (morbid obesity). The lean subjects were 145
years old and had never had BMI 125 according to self-report.
The aim of selecting subjects with an extreme BMI phenotype in
sample 1 was to enrich for a genetic impact on obesity or lean-
ness.12 This was also the purpose of recruiting young obese adults,
since early onset of this disorder is believed to have a stronger
genetic component because of the reduced time of environmental
impact.12 A total of 59 obese subjects had oral treatment for type
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Figure 1. Schematic presentation of ascertainment schemes for
samples 1–3.
Table 1. Characteristics of the Cohorts
Sample, Country,
Body Weight Status,
and Sex n
Agea
(years) BMIa
1:
Sweden:
Obese:
F 487 42  13 (16–77) 44  4 (30–64)
M 124 45  13 (16–73) 45  5 (32–58)
Lean:
F 338 50  4 (46–68) 22  2 (15–25)
M 64 57  8 (46–79) 23  2 (18–25)
2:
Sweden:
Obese:
F 688 44  11 (19–75) 36  4 (30–58)
M 122 45  13 (18–75) 44  5 (31–66)
Lean:
F 525 39  6 (25–61) 22  2 (17–25)
M 88 36  11 (26–49) 23  1 (19–25)
3:
Sweden:
Nonobese:
F 99 38  10 (18–60) 23  2 (18–27)
M 51 41  11 (26–77) 23  2 (19–25)
4:
Denmark:
Anyb:
F 3,854 48  10 (22–88) 26  5 (15–56)
M 3,937 49  10 (19–89) 27  4 (17–57)
a Values are mean  SD (range)
b Ascertainment was population based.
2 diabetes, but otherwise the subjects in sample 1 were healthy
according to self-report.
Sample 2, used for conﬁrmation of genetic associations, was
recruited from the same sources but according to less stringent
deﬁnitions for lean and obese phenotypes than those used for
sample 1 (ﬁg. 1 and table 1). The obese subjects had BMI 130 at
any age, and the lean subjects were 125 years old and had BMI
!25. The reason for the less stringent lean or obese phenotype
criteria in sample 2 was practical—it is difﬁcult to ﬁnd subjects
fulﬁlling the extreme criteria chosen for sample 1. The possibly
resulting reduced power was partially overcome by a larger sample
size. Sample 2 also comprised subjects who were at least 2nd-
generation Scandinavians living in Sweden. Of the obese subjects
in sample 2, 197 had hypertension, 116 had type 2 diabetes, and
50 had dyslipidemia, but otherwise the subjects were healthy
according to self-report.
Sample 3 comprised healthy, nonobese Swedish subjects who
were at least 2nd-generation Scandinavians and did not use any
continuous medication. They were recruited through local ad-
vertisement with the purpose of studying metabolic regulation
in fat cells (ﬁg. 1 and table 1). Those subjects in sample 3 who
fulﬁlled the criteria for inclusion in samples 1 and 2 were also
included in samples 1 and 2 (ﬁg. 1 and table 1). In the morning
after an overnight fast, a subcutaneous fat biopsy specimen was
obtained from the abdominal area by needle biopsy.13
Sample 4 consisted of a population-based Danish cohort of
middle-aged people (3,937 men and 3,854 women) recruited as
reported elsewhere.14 Clinical details of these subjects have been
reported elsewhere.15
All subjects were age 18 years or older and were recruited in-
dependently of one another. Thus, there is no known familial
relation between recruited subjects. We included both men and
women in our analysis because genetic analyses of obesity indi-
cate that themajority of susceptibility alleles are common in both
sexes.16,17 Our recruitment strategy for samples 1 and 2 resulted
in a higher proportion of women than men in the study. How-
ever, in both samples, the ratio of women to men were similar
among obese and lean subjects.
All subjects came to the laboratory in the morning after an
overnight fast. Height, weight, and, for the majority of subjects,
waist circumference (midway between the lower rib-margin and
the iliac crest), and hip circumference (widest measure over the
great trochanters) were measured. The circumferences were mea-
sured in the supine position at the end of gentle expiration. A
venous blood sample was obtained for extraction of genomic
DNA and for determination of serum insulin, plasma glucose,
lipids, glycerol, and free fatty acids by the accredited laboratories
of the hospitals. Insulin resistance index (by homeostasis model
assessment) (HOMAIR) was calculated as fasting serum insulin
(mU/liter) times fasting plasma glucose (mmol/liter) divided by
22.5.18 Measures of serum insulin, plasma glucose, and plasma
lipids were available for 1,809–1,977 subjects in samples 1 and
2. In vivo lipolytic activity was available for ∼1,900 subjects in
samples 1 and 2 and was determined as plasma glycerol or free
fatty acid concentrations divided by total body fat. Total body
fat was obtained by a formula based on age, BMI, and sex.19 We
compared body fat calculated in this way with the “golden stan-
dard,” which is dual x-ray absorptiometric analysis, for 11 non-
obese (BMI 16.5–27.7) and 10 obese (BMI 30.2–45.9) subjects.
Mean coefﬁcient of variance between the two measures was 4%
in nonobese subjects and 3.7% in obese subjects, suggesting that
the formula method was sufﬁciently accurate.
The study was approved by the local ethics committee at each
site, and informed consent was obtained from the subjects.
Studies of Mature Fat Cells
The investigations of mature fat cells were performed for sample
3. Lipolysis in isolated fat cells was investigated as described
elsewhere.20,21 Cell suspensions were incubated in the absence or
presence of increasing concentrations of noradrenaline, the b1-
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Figure 2. GPR74 SNPs and haplotypes. Bold font indicates SNPs
with a call rate 190% and a frequency 15% that were used for
inferring the haplotypes. Allelic frequency of speciﬁc GPR74 hap-
lotypes in obese case patients ( ) and lean control subjectsnp 611
( ) in sample 1 analyzed with Haploview. Haplotype P pnp 402
mean  SD (lower value of range) of probabilities by which hap-
lotypes have been assigned to individuals. P values were calculated
by x2 test for signiﬁcance of the difference in haplotype frequency
between cases and controls. An asterisk (*) indicates signiﬁcant
difference in ATAG haplotype frequency between cases and control
s in joint analysis of samples 1 and 2; .Pp .0014
selective adrenoceptor agonist dobutamine, the b2-adrenoceptor
selective agonist terbutaline, and the a2-adrenoceptor selective
agonist clonidine. The concentration (log of mol/liter) of agonist
causing half the maximum effect was determined. This value was
converted to its negative form (pD2), which reﬂects agonist sen-
sitivity. The maximum effect was determined as glycerol release
(lipolysis index) at the maximum effective agonist concentration
and was related to the number of incubated fat cells.
Studies of Preadipocytes
Subcutaneous adipose tissue was obtained from patients under-
going cosmetic lipoaspiration (eight women and one man; mean
[SD] age 38  13 years; age range 19–60 years; BMI [SD] 29
 5; BMI range 22–39). Five adipose tissue samples were from
the abdominal area; for the other samples, information about the
source location was lacking. The isolation and differentiation of
preadipocytes was performed as described elsewhere.22
In one type of experiment, preadipocytes were treated with a
maximum effective concentration (106 mol/liter) of NPFF4 for 3
h or 48 h before lipolysis experiments, which were performed at
day 12 or 13 of differentiation. In the second type of experiment,
RNA interference was investigated as described elsewhere.23 Dif-
ferent amounts of GPR74 siRNA (1–3 mg) and the transfection
reagent RNAiFect/HiPerFect (Qiagen) were titrated to determine
the optimal conditions for GPR74 silencing. The preadipocytes
were transfected at day 7 of the differentiation process with 2.3
mg of GPR74 siRNA or scrambled (nonsilencing) siRNA. The cells
treated with only the transfection agent served as controls. After
24 hours, some cells were lysed for RNA isolation to determine
the silencing efﬁciency. The remaining cells were used for lipolysis
and adipocyte differentiation assays.
mRNA levels were determined as described elsewhere.23 Total
RNA was extracted and was reverse transcribed to cDNA. Quan-
titative real-time PCR was performed in an iCycler IQ (Bio-
Rad Laboratories). GPR74 and 18S mRNA were quantiﬁed using
TaqMan kits (Applied Biosystems). Expression of GPR74 mRNA
was normalized to the 18S internal control by use of the formula
(C GPR74 calibrator  C GPR74 sample)t t2
,(C 18S calibrator  C 18S sample)t t2
where calibrator is a random sample.
Preadipocyte differentiation was measured by quantifying the
glycerol-3-phosphate dehydrogenase (GPDH) activity, as de-
scribed elsewhere.22 Cell proteins were extracted, and GPDH ac-
tivity and protein concentration were measured spectrophoto-
metrically. Treatment with NPFF or siRNA against GPR74 did not
inﬂuence preadipocyte differentiation, as evidenced by theGPDH
measurements.
Lipolysis experiments on differentiated preadipocytes were per-
formed after the NPFF treatment or siRNA transfection at day 12
or 13 of differentiation, as described elsewhere.22 Cells were in-
cubated for 3 h with or without 104 mol/liter of noradrenaline
alone or in combination with 104 mol/liter of the a2-adreno-
ceptor selective blocker yohimbine or 103 mol/liter of the phos-
phodiesterase-resistant cyclic AMP analogue, dibutyryl cyclic
AMP. Glycerol concentration in the medium was measured and
was related to the amount of cellular protein, because cell number
cannot be measured in these conditions.
Genotyping
DNA was extracted and puriﬁed using a kit procedure (Qiagen).
GPR74 genotype information for a region covering from ∼10,000
bp upstream of exon 1 to 10,000 bp downstream of exon 4 was
downloaded from the International HapMap Project. Genotype
data for the population of individuals of European ancestry were
visualized using Haploview. SNPs for genotyping were selected
on the basis of the following criteria: (1) SNPs deﬁninghaplotypes
with frequency 15% and (2) one SNP with frequency 12% every
5,000 bp. In selecting between different SNPs, we prioritized SNPs
with Golden-Gate–validated assays or with a high score according
to Illumina,24 which indicates that the designed Illumina geno-
typing assays are likely to work.
Subjects in sample 1 and 3 were genotyped using Illumina.24
Samples 2 and 4 were genotyped using matrix-assisted laser de-
sorption/ionization time-of-ﬂight mass spectrometry (SEQUE-
NOM) as described elsewhere.25 For both genotyping platforms,
the overall genotype call rate was 96% and the accuracy was
99.99%, according to duplicate analysis of, on average, 2% of the
total genotypes. Primers are available on request. Two indepen-
dent scorers conﬁrmed all genotypes. Hardy-Weinberg calcula-
tions were performed to ensure that each marker was in popu-
lation equilibrium.
Sequencing
To identify promoter or coding SNPs carried by the ATAG hap-
lotype, we sequenced all GPR74 exons, the exon-intron borders,
and 1,730 bp 5′ of exon 1 in ﬁve subjects homozygous for ATAG
and in three subjects who did not carry ATAG. We failed to se-
quence further 5′ because of a repeat region. Staden software was
used for sequence assembly. All sequences were scored manually
for the presence of SNPs.
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Table 2. GPR74 SNPs
SNP Region Positiona Alleles
Allele
Frequencyb
(%)
Call
Rate
(%)
HWE
P
rs6817845 5′ 73259416 … NP 97.7 …
rs6856651 5′ 73261492 ArT 29.0 100.0 .34
rs6446796 Intron 1 73264126 TrC 30.2 76.8 .021c
rs6824342 Intron 1 73268217 TrC 30.0 100.0 .39
rs13150414 Intron 1 73270871 GrT 30.2 99.7 .47
rs9637554 Intron 1 73278192 CrG 1.6 94.7 .42
rs4694453 Intron 1 73284045 CrA .9 100.0 .19
rs11938755 Intron 1 73286432 GrA 1.7 98.5 .51
rs6446809 Intron 1 73290529 TrG .1 100.0 1
rs4353870 Intron 1 73297930 ArT 1.7 99.9 .5
rs4694462 Intron 1 73302773 CrG 1.7 100.0 .5
rs12642985 Intron 1 73312934 CrT 30.2 98.8 .38
rs9993413 Intron 1 73319113 CrT .2 99.9 1
rs12510838 Intron 1 73326573 ArG 17.3 99.5 .78
rs4129733 Intron 1 73328055 TrG 35.7 98.0 .42
rs7662933 Intron 1 73335910 … NP 98.0 …
rs13107347 Intron 1 73339783 … … .0 …
rs4264803 Intron 1 73343505 … … .0 …
rs9291171 Intron 1 73346661 ArG 28.9 92.1 .22
rs11940192 Intron 1 73356942 … … .0 …
rs7679840 Intron 2 73362944 CrT .1 100.0 1
rs12650900 Intron 2 73367493 … NP 98.0 …
rs11940196 Intron 2 73368604 ArG 38.7 97.6 .27
rs6826854 Intron 3 73373464 CrT .1 99.9 1
rs17775309 3′ 73382993 TrG 32.4 87.9 .13
a Position on chromosome 4, genome build 35.
b NP p nonpolymorphic.
c HWE among controls.
Statistical Analysis
Haploview was employed to calculate Hardy-Weinberg P values
and linkage disequilibrium, to infer haplotypes, and to test for
allelic and haplotype association with obesity. Linkage disequi-
librium was calculated as D′. For deﬁning haploblocks, 95% con-
ﬁdence bounds on D′ were generated, and each comparison was
classiﬁed as “strong LD,” “inconclusive,” or “strong recombina-
tion.” A block was created when 95% of informative (i.e., not
inconclusive) comparisons showed “strong LD.” This method, by
default, ignores markers with minor-allele frequency !0.05. An
accelerated expectation-maximization algorithm similar to the
partition/ligation method described by Qin et al.26 was used in
Haploview to estimate haplotypes. This creates highly accurate
population-frequency estimates of the phased haplotypes on the
basis of the maximum likelihood as determined from the un-
phased input. In single-locus and multimarker haplotype-asso-
ciation tests, the x2 and P value for the allele frequencies in cases
versus controls were calculated. The haplotype analysis counts
for the association analysis were obtained by summing the frac-
tional likelihoods of each individual for each haplotype. Individ-
uals with 150% missing genotypes were excluded from analysis.
It is not possible in Haploview to visualize the probabilities of
each individual’s estimated haplotypes. Therefore, SNPHAP,
which uses a method similar to Haploview to infer haplotypes,
was used to assign probabilities to each individual’s estimated
haplotypes. Odds ratios (ORs) were calculated using the Finetti
software (Hardy-Weinberg equilibrium Web site). We did not ad-
just for hypertension, type 2 diabetes, or dyslipidemia because,
in obese subjects, these phenotypes are usually the consequence
of obesity.
In samples 1 and 2, which were ascertained on the basis of
obesity status, waist circumference was analyzed by Mann-Whit-
ney U test (Statview). In sample 4, which was population-based
and thus not ascertained on the basis of analyzed phenotypes,
we applied an analysis of the quantitative trait waist or BMI by
using analysis of covariance (ANCOVA) with age as covariate.
HOMAIR, plasma lipid, plasma glucose, and serum insulin are de-
pendent on adiposity and age. In samples 1 and 2, these phe-
notypes were analyzed by ANCOVA, with stratiﬁcation for obesity
status and with age as covariate. In sample 4, these phenotypes
were analyzed by ANCOVA with age and BMI as covariates. To
study in vivo lipolysis, which was already corrected for body fat,
we employed ANCOVA with age as covariate. In vitro lipolysis
phenotypes in the nonobese sample 3 were analyzed by ANCOVA
with age and BMI as covariates. Sex has impact on the analyzed
phenotypes; therefore, we repeated all ANCOVA analyses with
stratiﬁcation for sex. We report nonadjusted results of ANOVA
because the different adjustments of P values described above did
not, in any case, make an important change in the P values,which
usually were identical with the P values fromANOVA. All reported
P values are nominal, unless otherwise stated. A permutation test
with 10,000 permutations was used to adjust signiﬁcance in the
initial analysis of association between the ATAG haplotype and
obesity. For conﬁrmation, when one hypothesis was tested, no
correction for multiple comparisons was used. Bonferroni cor-
rection for the number of comparisons was applied when mul-
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Table 3. Association of GPR74 SNPs with Obesity in Samples 1 and 2
Sample
and Marker
No. of Chromosomes
P
Cases Controls Allele Frequency
Allele 1 Allele 2 Allele 1 Allele 2 Cases Controls
1:
rs6856651 365 813 206 592 .31 .26 .013
rs6824342 377 801 216 582 .32 .27 .019
rs13150414 378 794 217 581 .32 .27 .016
rs9637554 1,076 10 766 20 .99 .98 .0058
rs4694453 1,168 10 788 10 .99 .99 .38
rs11938755 1,140 14 772 20 .99 .98 .03
rs6446809 1,177 1 797 1 .999 .999 .78
rs4353870 1,162 14 778 20 .99 .98 .027
rs4694462 1,164 14 778 20 .99 .98 .027
rs12642985 372 782 217 581 .32 .27 .017
rs9993413 1,174 2 796 2 .998 .997 .7
rs12510838 216 956 124 670 .18 .16 .11
rs4129733 737 403 508 288 .65 .64 .7076
rs9291171 336 700 190 594 .32 .24 .0004
rs7679840 2 1176 0 798 .002 .000 .24
rs11940196 714 424 467 323 .63 .59 .11
rs6826854 1,175 1 776 0 .00 .00 .41
rs17775309 663 299 510 264 .69 .66 .18
2:
rs6856651 456 1138 354 862 .29 .29 .77
rs9637554 1,581 21 1,202 20 .99 .98 .47
rs12510838 293 1315 228 992 .18 .19 .75
rs4129733 1,035 575 825 395 .64 .68 .064
rs9291171 460 1148 351 863 .29 .29 .86
rs11940196 1,014 582 795 423 .64 .65 .34
tiple phenotypes were analyzed—for example, in analysis of the
adipocyte lipolysis data.
Results
The recruitment criteria for sample 1, which aimed to re-
cruit subjects with extreme phenotypes and with high or
no predisposition to obesity, resulted in obese subjects that
were younger (mean age 44 years) than the lean subjects
(mean age 52 years) (table 1). In addition, less stringent
BMI recruitment criteria for sample 2 resulted in pheno-
typic differences between samples 1 and 2 (table 1). In
sample 2, the mean age among obese subjects (44 years)
was similar to that in sample 1, whereas the lean subjects
were younger (mean age 39 years). The obese subjects in
sample 1 had a mean BMI of 45, and, in sample 2, the
obese subjects had a mean BMI of 38. In summary, sample
4 comprised 775 obese women and 793 obese men with
BMI 130 (mean age 51 9 years; BMI 34 4) and 3,079
nonobese women and 3,144 nonobese men (mean age 48
 10 years; BMI 25  3) (table 1). Thus, the subjects in
the Danish sample 4 were older and less obese than those
in Swedish samples 1 and 2.
We initially investigated sample 1, which had the most-
rigorous selection criteria for a lean or obese phenotype,
for SNPs covering the GPR74 gene selected from the In-
ternational HapMap Project (ﬁg. 2). Of the 25 SNPs tested
in genotyping assays, 3 failed to show association (12%),
which is close to the expected 10% failure rate, and 3 were
nonpolymorphic (table 2). Of the remaining 19 GPR74
SNPs, 9 were nominally associated with obesity in sample
1—2 of these, rs9637554 and rs9291171, were more
strongly associated, with P values of .0058 and .0004, re-
spectively (table 3). rs6446796 displayed a low call rate
and was therefore excluded from analysis of allelic asso-
ciation. Single SNPs associated with obesity with P values
!.01, as well as SNPs that deﬁned obesity-associated hap-
lotypes, were genotyped in a second cohort of lean or
obese Swedes, sample 2, which had less rigorous selection
criteria for leanness (age 125 years and BMI !25) and obe-
sity (BMI 130 at any age) than those of sample 1. In sample
2, no allelic difference between the lean and obese groups
was observed (table 3). Since 80%–85% of subjects in sam-
ples 1 and 2 were women, no sex-speciﬁc analysis was
performed.
In general, there was strong LD between SNPs in the
GPR74 gene (ﬁg. 3). The nine GPR74 SNPs with frequency
15% were used to infer haplotypes. Because haplotypes
inferred from unrelated subjects have uncertainty, we also
present mean  SD values (and the lower value of the
range) for the probability by which haplotypes have been
assigned to individual chromosomes in sample 1 (ﬁg. 2).
In sample 1, three haplotypes differed in frequency be-
tween lean and obese groups, with P values .0076–.022
(ﬁg. 2). Two of these haplotypes shared a common ATAG
motif at SNPs rs12510838, rs4129733, rs9291171, and
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Figure 3. Linkage disequilibrium (D′) between GPR74 SNPs in sample 1, according to Haploview analysis
rs11940196. Haplotypes with the ATAG motif were in-
ferred with high conﬁdence, with haplotype probability
mean 1.00 (lower value of range 0.95) (ﬁg. 2). In sample
1, the ATAG haplotype was associated with obesity, with
nominal P value .0014, and the OR for obesity was 0.48
(95% CI 0.30–0.76) (table 4). The permutated P value was
.0070. The association between the ATAG haplotype and
obesity was conﬁrmed in sample 2, with nominal P value
.014 and OR 0.62 (95% CI 0.42–0.90) (table 4). Pooling
samples 1 and 2 gave a P value of .000089. The ORs for
obesity of 0.48 and 0.62 for samples 1 and 2, respectively,
suggest that ATAG protects against obesity. ATAG was not
associated with obesity in the initial analysis of theDanish
sample 4. However, when sample 4 was enriched for sub-
jects at either end of the BMI distribution, including only
elderly lean subjects (BMI !25; age 145 years) or severely
obese subjects (BMI 135) in the analysis, ATAG was as-
sociated with protection against obesity in men, with
nominal P value .036 and OR 0.36 (95% CI 0.14–0.94).
The other haplotype associated with obesity in sample 1,
deﬁned by alleles ATGA at SNPs rs12510838, rs4129733,
rs9291171, and rs11940196, displayed no associationwith
obesity in sample 2 and weak opposite association in sam-
ple 4 and was not further investigated.
The inﬂuence of the ATAG haplotype on body com-
position and metabolic phenotypes was subsequently ex-
amined. A joint analysis of men in samples 1 and 2 was
performed because of the small number of men in these
samples. In samples 1 and 2, both men and women car-
rying ATAG had smaller waists than did those who carried
two other haplotypes (ﬁg. 4A and 4B). In sample 4, men
but not women carrying ATAG had signiﬁcantly smaller
waists than did noncarriers (ﬁg. 4). There was no effect of
ATAG on plasma glucose, serum insulin, HOMAIR, or
plasma lipids among men or women in sample 1, 2, or 4
(data not shown).
The relationship between the ATAG haplotype and li-
polysis was investigated next (ﬁg. 5). Plasma levels of glyc-
erol and free fatty acids, adjusted for total body fat, were
signiﬁcantly elevated among subjects carrying ATAG (ﬁg.
5A and 5B). With regard to in vitro data on human fat
cells in sample 4, the lipolytic sensitivity (pD2) of nor-
adrenaline was increased 10-fold among nonobese sub-
jects carrying ATAG, compared with nonobese subjects
who were noncarriers (ﬁg. 5C). The increased noradren-
aline sensitivity could be attributed to a 10-fold increase
in b2-adrenoceptor sensitivity (pD2 for terbutaline) (ﬁg.
5C). These results remained signiﬁcant after Bonferroni
correction for analysis of four adrenergic drugs. There was
no effect of ATAG on b1-adrenoceptor sensitivity (pD2 for
dobutamine) or on a2-adrenoceptor sensitivity (pD2 for
clonidine) (ﬁg. 5C). Likewise, the spontaneous or basal
lipolytic activity and the maximum lipolytic effect of li-
polysis stimulation were not altered in ATAG-carrying sub-
jects (results not shown).
The role of GPR74 in regulation of human adipocyte
lipolysis was investigated using a natural ligand with high
afﬁnity for GPR74, NPFF (ﬁg. 6). Short- or long-term ex-
posure of human fat cells in primary culture to NPFF,
which was added at a maximum effective concentration
for adipocytes, showed that the neuropeptide markedly
counteracted the lipolytic effect of noradrenaline alone
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Table 4. Association of GPR74 Haplotypes with Obesity
Sample and
Haplotypea
Cases Controls
Haplotype
Frequency
P OR (95% CI)
No. of ATAG
or ATGA
Chromosomes
No. of Non-ATAG
or Non-ATGA
Chromosomes
No. of ATAG
or ATGA
Chromosomes
No. of Non-ATAG
or Non-ATGA
Chromosomes Cases Controls
1:
ATGA 152 1,024 70 728 .13 .09 .0042
ATAG 32 1,144 44 754 .027 .055 .0014 .48 (.30–.76)
2:
ATGA 170 1,444 125 1,093 .1 .1 .83
ATAG 51 1,563 61 1,157 .032 .05 .014 .62 (.42–.90)
1 and 2:
ATGA 320 2,466 195 1,819 .11 .097 .043
ATAG 83 2,703 105 1,909 .03 .052 .000089 .55 (.29–.87)
4:
ATGA 296 2,794 1,332 10,936 .096 .109 .04
ATAG 108 2,982 460 11,809 .035 .037 .51 .93 (.87–1.33)
a Haplotype for rs12510838, rs4129733, rs9291171, and rs11940196.
and together with a high concentration of yohimbine,
which blocks the a2-receptor–mediated effects of nor-
adrenaline (ﬁg. 6A). However, the lipolytic effect of a cyclic
AMP analogue, which stimulates lipolysis distal to b-ad-
renoceptor signaling, was not inﬂuenced by NPFF treat-
ment (ﬁg. 6A). Treatment of fat cells with siRNA oligo-
nucleotides against GPR74 caused a speciﬁc decrease of
GPR74 mRNA levels by ∼70% (ﬁg. 6B) and a speciﬁc
2.5-fold increase in noradrenaline induced lipolysis (ﬁg.
6C); there was no effect of a random (scrambled)
oligonucleotide.
No SNP was detected for the ATAG haplotype in the
sequencing of all GPR74 exons, exon-intron borders, and
1,730 bp upstream of exon 1 in ﬁve subjects homozygous
for ATAG and in three subjects not carrying ATAG. It was
sufﬁcient to investigate eight subjects because we specif-
ically searched for polymorphism linked to the ATAG
haplotype.
Discussion
In this study, the genetic variance in GPR74 has been in-
vestigated, to our knowledge, for the ﬁrst time. Our results,
which were generated with the use of three large cohorts,
suggest that GPR74 is in control of BMI. In two Swedish
samples carefully selected for leanness and obesity, we
found a common haplotype, ATAG, with allele frequency
4%, that displayed a strong negative association with obe-
sity. We also found a strong association between ATAG
and waist circumference in the two Swedish cohorts. Both
men and women carriers of ATAG had smaller waists than
did noncarriers. The allele frequency of ATAG was similar
in the population-based Danish sample 4. In sample 4,
ATAG was associated with protection against obesity in
analysis of lean and severely obese men and with waist
circumference among men.
The strength of a true causal association betweenobesity
and single markers or haplotypes can depend on pheno-
typic distributions for age and BMI. The different ascer-
tainment schemes used for samples 1 and 2, which re-
sulted in different age and BMI distributions, could
explain the inability to conﬁrm single-marker association
in sample 2. The phenotypic differences between samples
1 and 2 may also explain why the association between
ATAG and obesity status was weaker in sample 2. The
somewhat different results obtained in analysis of ATAG
in sample 4, compared with in samples 1 and 2, may be
because the Danish cohort was population based, the
obese subset contained no young subjects with obesity,
and only 8% in the sample had severe obesity.
The association of ATAG with obesity phenotypes could
not be explained by any single SNP. There are previous
reports from the analyses of complex traits that several
mutations on the same chromosome—that is, a haplo-
type—within a gene can interact and have a large effect
on the observed phenotype that cannot be explained by
the individual mutations. Examples include b2-adrenergic
receptor gene haplotypes and bronchodilator response,
ELAC2 and risk of prostate cancer, and the lipoprotein
lipase gene and cardiovascular disease.27–29
Our results discussed so far support the notion that the
GPR74 haplotype ATAG protects against obesity. This hap-
lotype is associated with leanness (BMI !25) and a smaller
waist. This latter result suggests that ATAGprotects against
central-fat accumulation, which is less common among
women. The observation that Danish women, in contrast
to Swedish women, were not protected by ATAG could be
more apparent than real, because the Swedishwomenhad,
on average, much larger waists than those of the Danish
women (ﬁg. 4B).
What is the mechanism of the protective effect of
ATAG? Data from samples 1 and 2 suggest that a high
ability to mobilize lipids from adipose tissue is an impor-
tant contributing factor. Plasma levels of the end products
of lipolysis—glycerol and free fatty acids—adjusted for to-
tal body fat, were signiﬁcantly elevated among subjects
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Figure 4. Association between carriage of GPR74 ATAG haplotype and waist circumference in men (A) and women (B). The blackened
bar represents subjects carrying the ATAG haplotype; the unblackened bar represents subjects not carrying ATAG. The frequencies of
haplotypes were as follows: in men in samples 1 and 2, ATAG p 19 and non-ATAG p 327; in men in sample 4, ATAG p 276 and non-
ATAG p 3,615; in women in sample 1, ATAG p 55 and non-ATAG p 667; in women in sample 2, ATAG p 78 and non-ATAG p 995;
in women in sample 4, ATAG p 262 and non-ATAG p 3,550. Samples 1 and 2 were analyzed by the Mann-Whitney U test, and sample
4 was analyzed using ANCOVA, with age as covariate.
Figure 5. A, Association between carriage of the ATAG haplotype and in vivo lipolysis measured as plasma glycerol corrected for body
fat. The blackened bar represents the 124 subjects carrying ATAG; the unblackened bar represents the 1,771 subjects not carrying ATAG.
B, Association between carriage of the ATAG haplotype and in vivo lipolysis measured as plasma free fatty acids corrected for body fat.
The blackened bar represents the 100 subjects carrying ATAG; the unblackened bar represents the 1,494 subjects not carrying ATAG. C,
Association between carriage of the ATAG haplotype and adipocyte lipolytic sensitivity (pD2) of different adrenergic agonists. The
blackened bar represents the 14 subjects carrying ATAG; the unblackened bar represents the 136 subjects not carrying ATAG. Analyzed
subjects came from samples 1 and 2. Groups were compared by ANCOVA, with age as covariate in panel A and with age and BMI as
covariates in panel B.
carrying ATAG. This ﬁnding may indicate that in vivo
lipolysis activity is increased among subjects with ATAG.
Our in vitro data for human fat cells from healthy non-
obese subjects (in sample 4) provide evidence that ATAG
improves the ability of catecholamines to stimulate li-
polysis. The lipolytic sensitivity of noradrenaline was 10-
fold increased among nonobese subjects carrying ATAG.
In biological terms, this means that a half-maximumstim-
ulatory effect of noradrenaline on lipolysis was obtained
at ∼1 nmol/liter in the subjects carrying ATAG and at ∼10
nmol/liter in other subjects; these concentrations are
within the normal physiological range. The increased nor-
adrenaline sensitivity could be attributed to a 10-fold in-
crease in b2-adrenoceptor sensitivity. There was no effect
of ATAG on b1-adrenoceptor sensitivity or on a2-adreno-
ceptor sensitivity.
For the moment, molecular studies of the effect of the
ATAG haplotype on GPR74 function are hampered by the
fact that the haplotype contains no SNPs in the putative
promoter, exons, or exon-intron borders. The lack of exon
SNPs makes allele-speciﬁc mRNA quantiﬁcation impossi-
ble. Intronic SNPs may also affect gene-transcript stability
and mRNA levels. Unfortunately, we did not have adipose
RNA from the number of subjects required to relate car-
riage of the ATAGhaplotype tomRNA levels. Nevertheless,
we provide, for the ﬁrst time, evidence of a role for GPR74
in regulation of adipocyte lipolysis by use of NPFF, which
is a natural ligand with high afﬁnity for GPR74.4 Short-
or long-term exposure of human fat cells in primary cul-
ture to NPFF markedly inhibited the lipolytic effect of nor-
adrenaline. Additional data with blockade of a2-receptor–
mediated effects of noradrenaline and with a cyclic AMP
analogue, which stimulates lipolysis distal to the b-adren-
oceptor, strongly suggest that GPR74 has inhibitory effects
on catecholamine-induced lipolysis by interference with
b-adrenoceptor signaling in fat cells. A more deﬁnitive
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Figure 6. A, Effect on human preadipocytes differentiated into adipocytes of the GPR74 agonist NPFF on lipolysis measured as plasma
glycerol (ﬁve experiments). The white bar represents controls, the blackened bar represents NPFF for 3 h, and the striped bar represents
NPFF for 48 h. B, Effect of siRNA against GPR74 on expression of GPR74 mRNA (four experiments). C, Effect of siRNA against GPR74
on lipolysis. The white bar represents no oligo, the gray shaded bar represents scrambled oligo, and the blackened bar represents GPR74
siRNA. Groups were compared by ANOVA.
proof of an inhibitory role of GPR74 on adipocyte lipoly-
sis was obtained by siRNA experiments with primary cul-
ture of human fat cells. A decrease of GPR74 mRNA was
accompanied by an increase in catecholamine-induced
lipolysis.
It is an attractive hypothesis that the ATAG haplotype
protects against fat accumulation by ameliorating the in-
trinsic inhibitory effect of GPR74 on lipolysis (seen in the
siRNA experiments). Interactions between GPR74 and b2-
adrenoceptors in adipocytes may be involved in the pro-
tective effect of ATAG (seen in the NPFF experiments and
ﬁndings with the haplotype and pD2). Interestingly, de-
creased adipocyte b2-adrenoceptor function is demon-
strated in human obesity,20,21 and polymorphisms in the
b2-adrenoceptor gene is related to adipocyte lipolysis and
body fat.30 It is quite possible, however, that the ATAG
haplotype has other nonadipocyte effects on body weight
that are mediated by NPFF, according to animal studies
(mentioned in the introduction). Thus, effects related to
cardiac regulation, stress response, reward, or food intake
may inﬂuence body weight regulation among subjects
with ATAG independent of the putative fat-cell effect.6–9
Obesity is accompanied by metabolic and hormonal
changes. In our cohorts, ATAG was not associated with
plasma levels of lipids and glucose, serum insulin, or HO-
MAIR as a measure of insulin resistance, which implies that
ATAG has no impact on these phenotypes. However, we
cannot exclude that ATAG would have a role in a sample
selected for more-extreme insulin-resistance phenotypes.
In conclusion, this study suggests that a commonGPR74
haplotype regulates body weight. Carriers of the ATAG
haplotype, ∼8% of the population in Scandinavian coun-
tries, are protected against excessive fat accumulation.
This may be the result of an increased ability to mobilize
lipids from adipose tissue because of a weakened inhibi-
tory effect of GPR74 on b2-adrenoceptor signaling in fat
cells. Because of the relationship between GPR74 poly-
morphisms, lipolysis, and body fat, it is tempting to sug-
gest that GPR74 blockers might be useful in the treatment
of obesity.
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